TERRASCEND CORP (TSND.CA) Stock Fundamental Analysis
TSX:TSND - Toronto Stock Exchange - CA88105E1088 - Common Stock - Currency: CAD
Taking everything into account, TSND scores 3 out of 10 in our fundamental rating. TSND was compared to 34 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of TSND have multiple concerns. TSND is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year TSND has reported negative net income.
In the past year TSND had a positive cash flow from operations.
TSND had negative earnings in 4 of the past 5 years.
TSND had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
TSND has a Return On Assets (-14.08%) which is comparable to the rest of the industry.
TSND has a Return On Equity of -44.90%. This is in the lower half of the industry: TSND underperforms 63.64% of its industry peers.
TSND has a better Return On Invested Capital (4.11%) than 81.82% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -14.08% | ||
| ROE | -44.9% | ||
| ROIC | 4.11% |
ROA(3y)-20.27%
ROA(5y)-27.85%
ROE(3y)-47.17%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
TSND's Operating Margin of 10.36% is amongst the best of the industry. TSND outperforms 84.85% of its industry peers.
TSND's Operating Margin has improved in the last couple of years.
The Gross Margin of TSND (48.42%) is better than 66.67% of its industry peers.
In the last couple of years the Gross Margin of TSND has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.36% | ||
| PM (TTM) | N/A | ||
| GM | 48.42% |
OM growth 3Y19.39%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.8%
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so TSND is destroying value.
The number of shares outstanding for TSND has been increased compared to 1 year ago.
Compared to 5 years ago, TSND has more shares outstanding
Compared to 1 year ago, TSND has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -0.64, we must say that TSND is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of TSND (-0.64) is comparable to the rest of the industry.
TSND has a debt to FCF ratio of 6.70. This is a slightly negative value and a sign of low solvency as TSND would need 6.70 years to pay back of all of its debts.
TSND has a better Debt to FCF ratio (6.70) than 75.76% of its industry peers.
TSND has a Debt/Equity ratio of 0.93. This is a neutral value indicating TSND is somewhat dependend on debt financing.
TSND has a worse Debt to Equity ratio (0.93) than 81.82% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.93 | ||
| Debt/FCF | 6.7 | ||
| Altman-Z | -0.64 |
ROIC/WACC0.4
WACC10.27%
2.3 Liquidity
A Current Ratio of 1.35 indicates that TSND should not have too much problems paying its short term obligations.
With a Current ratio value of 1.35, TSND is not doing good in the industry: 60.61% of the companies in the same industry are doing better.
TSND has a Quick Ratio of 1.35. This is a bad value and indicates that TSND is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of TSND (0.69) is worse than 69.70% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.35 | ||
| Quick Ratio | 0.69 |
3. Growth
3.1 Past
The earnings per share for TSND have decreased strongly by -166.67% in the last year.
The Revenue has been growing slightly by 7.33% in the past year.
Measured over the past years, TSND shows a very strong growth in Revenue. The Revenue has been growing by 126.70% on average per year.
EPS 1Y (TTM)-166.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-133.33%
Revenue 1Y (TTM)7.33%
Revenue growth 3Y29.01%
Revenue growth 5Y126.7%
Sales Q2Q%-16.89%
3.2 Future
Based on estimates for the next years, TSND will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.66% on average per year.
The Revenue is expected to grow by 6.32% on average over the next years.
EPS Next Y45.39%
EPS Next 2Y28.6%
EPS Next 3Y18.4%
EPS Next 5Y12.66%
Revenue Next Year-3.9%
Revenue Next 2Y-0.65%
Revenue Next 3Y5.43%
Revenue Next 5Y6.32%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for TSND. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TSND. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
TSND's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. TSND is cheaper than 87.88% of the companies in the same industry.
TSND's Price/Free Cash Flow ratio is rather cheap when compared to the industry. TSND is cheaper than 87.88% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 6.38 | ||
| EV/EBITDA | 6.52 |
4.3 Compensation for Growth
TSND's earnings are expected to grow with 18.40% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.6%
EPS Next 3Y18.4%
5. Dividend
5.1 Amount
TSND does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:TSND (2/21/2025, 7:00:00 PM)
0.76
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners36.02%
Inst Owner ChangeN/A
Ins Owners3.14%
Ins Owner ChangeN/A
Market Cap271.02M
Analysts82
Price Target2.92 (284.21%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-49.12%
Min EPS beat(2)-80.6%
Max EPS beat(2)-17.65%
EPS beat(4)0
Avg EPS beat(4)-306.19%
Min EPS beat(4)-997.71%
Max EPS beat(4)-17.65%
EPS beat(8)1
Avg EPS beat(8)-156.46%
EPS beat(12)2
Avg EPS beat(12)-332.66%
EPS beat(16)3
Avg EPS beat(16)-1201.21%
Revenue beat(2)0
Avg Revenue beat(2)-5.72%
Min Revenue beat(2)-6.01%
Max Revenue beat(2)-5.43%
Revenue beat(4)0
Avg Revenue beat(4)-4.85%
Min Revenue beat(4)-6.01%
Max Revenue beat(4)-2.92%
Revenue beat(8)2
Avg Revenue beat(8)-2.64%
Revenue beat(12)2
Avg Revenue beat(12)-5.93%
Revenue beat(16)2
Avg Revenue beat(16)-6.36%
PT rev (1m)-8.03%
PT rev (3m)-8.03%
EPS NQ rev (1m)-9.09%
EPS NQ rev (3m)-9.09%
EPS NY rev (1m)-2.91%
EPS NY rev (3m)-26.19%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.89%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.6 | ||
| P/FCF | 6.38 | ||
| P/OCF | 5.07 | ||
| P/B | 0.93 | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.52 |
EPS(TTM)-0.45
EYN/A
EPS(NY)-0.16
Fwd EYN/A
FCF(TTM)0.12
FCFY15.68%
OCF(TTM)0.15
OCFY19.71%
SpS1.27
BVpS0.82
TBVpS-0.44
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -14.08% | ||
| ROE | -44.9% | ||
| ROCE | 5.71% | ||
| ROIC | 4.11% | ||
| ROICexc | 4.32% | ||
| ROICexgc | 10.23% | ||
| OM | 10.36% | ||
| PM (TTM) | N/A | ||
| GM | 48.42% | ||
| FCFM | 9.39% |
ROA(3y)-20.27%
ROA(5y)-27.85%
ROE(3y)-47.17%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y43.47%
ROICexcg growth 5YN/A
ROICexc growth 3Y32.07%
ROICexc growth 5YN/A
OM growth 3Y19.39%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.8%
GM growth 5YN/A
F-Score5
Asset Turnover0.49
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.93 | ||
| Debt/FCF | 6.7 | ||
| Debt/EBITDA | 3.45 | ||
| Cap/Depr | 34.26% | ||
| Cap/Sales | 2.41% | ||
| Interest Coverage | 1.36 | ||
| Cash Conversion | 67.84% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.35 | ||
| Quick Ratio | 0.69 | ||
| Altman-Z | -0.64 |
F-Score5
WACC10.27%
ROIC/WACC0.4
Cap/Depr(3y)159.76%
Cap/Depr(5y)486.54%
Cap/Sales(3y)12.78%
Cap/Sales(5y)24.45%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-166.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-133.33%
EPS Next Y45.39%
EPS Next 2Y28.6%
EPS Next 3Y18.4%
EPS Next 5Y12.66%
Revenue 1Y (TTM)7.33%
Revenue growth 3Y29.01%
Revenue growth 5Y126.7%
Sales Q2Q%-16.89%
Revenue Next Year-3.9%
Revenue Next 2Y-0.65%
Revenue Next 3Y5.43%
Revenue Next 5Y6.32%
EBIT growth 1Y3.76%
EBIT growth 3Y54.02%
EBIT growth 5YN/A
EBIT Next Year53.83%
EBIT Next 3Y30.55%
EBIT Next 5Y23.52%
FCF growth 1Y129.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y157.84%
OCF growth 3YN/A
OCF growth 5YN/A